URGN

UroGen Pharma Ltd

Apr 07 • 04:00PM ET

18.03

-0.58 -3.12 %

Healthcare • Biotechnology • USA • NASD

Peers: SRPT BIIB EXEL IONS FOLD ACAD NBIX VKTX PBYI HALO

| Held by: IWM IBB IWO VTWO SPDW FESM VHT IZRL IWC CANC

Index	RUT	P/E	-	EPS (ttm)	-3.21	Insider Own	17.98%	Shs Outstand	48.35M	Perf Week	6.06%
Market Cap	877.74M	Forward P/E	19.65	EPS next Y	0.92	Insider Trans	-0.31%	Shs Float	39.93M	Perf Month	-11.88%
Enterprise Value	886.02M	PEG	-	EPS next Q	-0.50	Inst Own	82.23%	Short Float	21.61%	Perf Quarter	-18.53%
Income	-153.49M	P/S	7.99	EPS this Y	63.38%	Inst Trans	3.91%	Short Ratio	11.06	Perf Half Y	3.62%
Sales	109.79M	P/B	-	EPS next Y	178.54%	ROA	-63.14%	Short Interest	8.63M	Perf YTD	-23.01%
Book/sh	-2.18	P/C	7.21	EPS next 5Y	-	ROE	-	52W High	30.00 -39.90%	Perf Year	81.02%
Cash/sh	2.50	P/FCF	-	EPS past 3/5Y	12.81% 11.57%	ROIC	-671.51%	52W Low	3.42 427.19%	Perf 3Y	104.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	19.49% 56.22%	Gross Margin	88.66%	Volatility	5.00% 5.42%	Perf 5Y	-7.49%
Dividend TTM	-	EV/Sales	8.07	EPS Y/Y TTM	0.35%	Oper. Margin	-113.73%	ATR (14)	1.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.65	Sales Y/Y TTM	21.45%	Profit Margin	-139.81%	RSI (14)	44.59	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	4.01	EPS Q/Q	31.63%	SMA20	-1.22%	Beta	1.48	Target Price	35.62
Payout	-	Debt/Eq	-	Sales Q/Q	54.03%	SMA50	-8.56%	Rel Volume	0.65	Prev Close	18.61
Employees	291	LT Debt/Eq	-	Earnings	Mar 02 BMO	SMA200	-8.29%	Avg Volume	779.96K	Price	18.03
IPO	May 04, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-7.48% -5.20%	Trades		Volume	507,020	Change	-3.12%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-25	Initiated	Piper Sandler	Overweight	$36
Jun-16-25	Upgrade	H.C. Wainwright	Neutral → Buy	$50
May-22-25	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-16-25	Initiated	Scotiabank	Sector Outperform	$23
Feb-19-25	Resumed	Ladenburg Thalmann	Buy	$31
Aug-22-24	Initiated	Guggenheim	Buy	$40
Feb-08-23	Downgrade	Jefferies	Buy → Hold	$35 → $10
Apr-27-22	Initiated	Berenberg	Buy	$20
Apr-16-20	Reiterated	H.C. Wainwright	Buy	$53 → $57
Apr-13-20	Reiterated	H.C. Wainwright	Buy	$75 → $53
Jan-09-20	Initiated	National Securities	Neutral	$37
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy	$82
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy	$50
Nov-15-17	Reiterated	Oppenheimer	Outperform	$32 → $51
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

Show Previous Ratings

Mar-30-26 08:00AM	Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI (GlobeNewswire)
Mar-13-26 08:00AM	UroGen Applauds BCAN's New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence (GlobeNewswire)
Mar-06-26 04:10PM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-02-26 04:02PM	UroGen Pharma Ltd (URGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ... (GuruFocus.com) -12.35%
12:15PM	Urogen Pharma Q4 Earnings Call Highlights (MarketBeat)
09:10AM	Loading…
09:10AM	Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
08:30AM	UroGen Pharma Ltd. Q4 2025 Earnings Call Summary (Moby)
08:00AM	UroGen Announces ZUSDURI Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
07:55AM	UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors (GlobeNewswire)
Feb-27-26 08:30AM	ZUSDURI Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC (GlobeNewswire)
Feb-24-26 04:05PM	UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-23-26 08:00AM	UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026 (GlobeNewswire)
Feb-15-26 08:06PM	UroGen Pharma CEO Touts ZUSDURI Launch Momentum, J-Code Boost and Billion-Plus Peak Sales Target (MarketBeat)
Feb-04-26 08:00AM	UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit (GlobeNewswire)
Jan-06-26 08:37AM	UroGen Pharma says permanent J Code for ZUSDURI now in effect (TipRanks)
08:00AM	Loading…
Jan-05-26 08:00AM	Permanent J Code for ZUSDURI Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy (GlobeNewswire)
Dec-05-25 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.35%
Nov-25-25 08:00AM	UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-16-25 10:14PM	UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs (Insider Monkey)
Nov-06-25 04:20PM	UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com) +21.91%
09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:00AM	UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI Launch Gains Momentum (GlobeNewswire)
07:58AM	UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial (GlobeNewswire)
Nov-04-25 08:00AM	UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Oct-30-25 10:00AM	Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
08:00AM	UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025 (GlobeNewswire)
07:15AM	Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-29-25 10:00AM	Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-25 08:00AM	Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI Effective January 1, 2026 (GlobeNewswire) +9.91%
Oct-22-25 08:18AM	MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last? (Zacks)
08:00AM	Loading…
Oct-02-25 08:00AM	ZUSDURI Clinical Review Published in Reviews in Urology Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Sep-08-25 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.45%
Aug-21-25 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-08-25 03:25AM	UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... (GuruFocus.com)
Aug-07-25 09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.10%
08:00AM	UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 08:06AM	UroGens Zusduri benefit maintained in NMIBC Phase III study (Clinical Trials Arena)
Aug-05-25 08:00AM	UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jul-30-25 09:10AM	LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss (Zacks)
Jul-29-25 08:00AM	UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 (GlobeNewswire)
01:31AM	UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology (Insider Monkey)
Jul-28-25 08:00AM	UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology (GlobeNewswire)
Jul-21-25 11:02AM	3 Bullish Biotech Stocks With Explosive Growth Trends (MarketBeat)
08:00AM	UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jul-08-25 11:48AM	UroGen concludes enrolment in Phase III trial of UGN-103 for bladder cancer (Clinical Trials Arena)
Jul-07-25 08:00AM	UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jul-06-25 04:01AM	UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer (Insider Monkey)
Jun-17-25 01:32PM	H.C. Wainwright Sees Billion Dollar Potential in UroGen's New Therapy (Insider Monkey) -7.67%
Jun-13-25 12:40PM	FDA approves UroGens Zusduri for non-muscle invasive bladder cancer (TipRanks) +8.57%
06:00AM	AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans (BioPharma Dive)
05:45AM	UroGen Pharma Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 28, 2025 to Discuss Your Rights - URGN (PR Newswire)
Jun-12-25 01:28PM	U.S. FDA Approves UroGens ZUSDURI (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire) +51.78%
Jun-06-25 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +43.39%
Jun-02-25 11:00AM	UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer (Business Wire) +14.15%
10:00AM	UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire)
May-29-25 01:45PM	UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman (PR Newswire)
May-27-25 04:00PM	UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA (Business Wire) -6.21%
May-22-25 06:52AM	FDA advisers pan Pfizers PARP drug; Sarepta to resume Duchenne study (BioPharma Dive)
May-21-25 12:17PM	UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire) -44.69%
May-20-25 10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -5.40%
May-13-25 03:05AM	UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... (GuruFocus.com) -8.98%
May-12-25 09:15AM	Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +7.32%
08:00AM	UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
May-07-25 10:32AM	Pfizer, J&J, Genentech drugs subject of FDA advisory panel meeting this month (Seeking Alpha)
10:22AM	UroGen's bladder cancer treatment to be reviewed by FDA advisory committee (Seeking Alpha)
08:57AM	UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
May-01-25 04:00PM	UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (Business Wire)
Apr-29-25 05:16AM	Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? (Zacks)
Apr-27-25 04:00PM	OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment (Business Wire)
01:00PM	New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC (Business Wire)
12:30PM	New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC (Business Wire)
Apr-26-25 06:30PM	UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire)
10:00AM	UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer (Business Wire)
Apr-14-25 08:00AM	UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers (Business Wire)
Apr-12-25 10:02AM	UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy (Seeking Alpha)
Mar-12-25 03:00PM	UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
Mar-10-25 09:10AM	Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 (Business Wire)
Mar-07-25 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 08:00AM	UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 (Business Wire)
Feb-25-25 12:30PM	Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? (Insider Monkey)
Feb-24-25 04:00PM	UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-21-25 10:53AM	UroGen acquires IconOVirs oncolytic virus assets (Pharmaceutical Technology) -5.88%
Feb-20-25 08:00AM	UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations (Business Wire)
Feb-14-25 02:30PM	UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 (Business Wire)
Feb-12-25 08:00AM	Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology (Business Wire)
Jan-30-25 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
Jan-22-25 08:00AM	New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) (Business Wire)
Jan-15-25 08:00AM	ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 (Business Wire)
Dec-06-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-05-24 03:30PM	Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO (Business Wire)
03:15PM	UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC (Business Wire)
Dec-02-24 05:44PM	Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade (Zacks)
08:00AM	UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs (Business Wire)
Nov-28-24 11:49AM	UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment (Clinical Trials Arena)
Nov-26-24 08:00AM	New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO (Business Wire)
Nov-07-24 02:16AM	UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Nov-06-24 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 (Business Wire)
Nov-05-24 08:00AM	UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference (Business Wire)

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Jason Drew	General Counsel	Feb 03 '26	Sale	19.69	7,479	147,262	51,326	Feb 11 02:54 PM
Schoenberg Mark	Chief Medical Officer	Feb 03 '26	Sale	19.69	7,373	145,174	144,985	Feb 04 07:37 PM
Schoenberg Mark	Officer	Feb 02 '26	Proposed Sale	19.61	13,333	261,460		Feb 03 07:53 AM
Schoenberg Mark	Chief Medical Officer	Nov 19 '25	Sale	25.00	10,000	250,000	139,025	Nov 20 01:42 PM
Schoenberg Mark	Officer	Nov 19 '25	Proposed Sale	25.00	10,000	250,005		Nov 19 03:19 PM
Degnan Chris	Chief Financial Officer	Oct 08 '25	Sale	16.85	2,203	37,121	2,280	Oct 09 01:37 PM
Schoenberg Mark	Chief Medical Officer	Sep 08 '25	Sale	19.11	871	16,645	149,025	Sep 09 06:37 PM
Smith Jason Drew	General Counsel	Sep 08 '25	Sale	19.11	1,520	29,047	43,305	Sep 09 06:32 PM
Schoenberg Mark	Officer	Sep 08 '25	Proposed Sale	18.88	871	16,444		Sep 09 09:51 AM
Smith Jason Drew	Officer	Sep 08 '25	Proposed Sale	18.88	1,520	28,698		Sep 09 07:59 AM
Schoenberg Mark	Chief Medical Officer	Aug 11 '25	Sale	17.69	10,000	176,900	148,229	Aug 13 09:58 AM
Smith Jason Drew	General Counsel	Jul 28 '25	Sale	19.14	7,522	143,971	41,492	Jul 30 04:03 PM
Schoenberg Mark	Chief Medical Officer	Jul 28 '25	Sale	19.14	5,149	98,552	158,229	Jul 30 04:02 PM
Schoenberg Mark	Officer	Jul 28 '25	Proposed Sale	18.95	5,149	97,574		Jul 29 07:29 AM
Smith Jason Drew	Officer	Jul 28 '25	Proposed Sale	18.95	7,522	142,542		Jul 29 07:23 AM
Schoenberg Mark	Chief Medical Officer	Jun 09 '25	Sale	7.37	5,162	38,044	153,378	Jun 11 09:14 AM
Schoenberg Mark	Officer	Jun 09 '25	Proposed Sale	7.37	5,162	38,044		Jun 10 09:27 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

URGN

UroGen Pharma Ltd

Upgrade your Finviz experience